Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1Dermatologic 1CNS 1

Conditions

Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Sarcoma 6Rhabdomyosarcoma 5Prostatic Neoplasms 5Sarcoma, Synovial 3Osteosarcoma 3Neuroectodermal Tumors, Primitive, Peripheral 3Carcinoma, Hepatocellular 3Breast Neoplasms 3Sarcoma, Ewing 2Neoplasm Metastasis 2Lung Neoplasms 2Liposarcoma 2Leiomyosarcoma 2Hemangiosarcoma 2Head and Neck Neoplasms 2Fibrosarcoma 2Colorectal Neoplasms 2Adrenocortical Carcinoma 2Zollinger-Ellison Syndrome 1Wilms Tumor 1Uveal Melanoma 1Unspecified Childhood Solid Tumor, Protocol Specific 1Squamous Cell Carcinoma of Head and Neck 1Somatostatinoma 1Small Cell Lung Carcinoma 1Retinoblastoma 1Rectal Neoplasms 1Pinealoma 1

Interventions

Octreotide 4Everolimus 4Capecitabine 4Temozolomide 3Leucovorin 3vatalanib 2fluorodopa F 18 2Trastuzumab 2Oxaliplatin 2Fluorouracil 2Bortezomib 2Bevacizumab 268Ga-NOTA-exendin-4 2veliparib 1tipifarnib 1romidepsin 1regorafenib 1pentetreotide 1pazopanib 1pasireotide 1motesanib diphosphate 1cixutumumab 1batifiban 1Thalidomide 1Surgical Procedures, Operative 1Streptozocin 1Sorafenib 1Solutions 1Salts 1Saline Solution 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Insulinoma × cixutumumab × Clear all
NCT01204476 2016-07-15

Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma

National Cancer Institute (NCI)

Phase 1 Completed
27 enrolled
CNSDermatologicEndocrine

Glucagonoma, Insulinoma, Paraganglioma, Somatostatinoma, Zollinger-Ellison Syndrome, Carcinoma, Merkel Cell, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡